Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher H Lieu

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Cancers|April 27, 2024
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid TumorsS Lindsey Davis, Wells A Messersmith, W Thomas Purcell, et al.
Liver Cancer|May 14, 2026
A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular CarcinomaAnthony B El-Khoueiry, Christopher H Lieu, Ghassan K Abou-Alfa, et al.
Plos One|April 10, 2024
Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL)Hayley J Hawkins, Betelehem W Yacob, Monica E Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2017
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal CancerEfrat Dotan, Steven J Cohen, Alexander N Starodub, et al.
JAMA Network Open|May 24, 2024
Red Flag Signs and Symptoms for Patients With Early-Onset Colorectal Cancer: A Systematic Review and Meta-AnalysisJoshua Demb, Jennifer M Kolb, Jonathan Dounel, et al.
Frontiers in Oncology|April 16, 2026
Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer modelRobert W Lentz, Adrian T A Dominguez, Nicole Baranda Balmaceda, et al.
Molecular Cancer Therapeutics|January 30, 2016
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian CancerColin D Weekes, Laetitia E Lamberts, Mitesh J Borad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2020
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Scott Kopetz, Katherine A Guthrie, Van K Morris, et al.
Frontiers in Oncology|November 24, 2022
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse modelsJulie Lang, Alexis D Leal, Juan A Marín-Jiménez, et al.
Cancer Research|July 26, 2018
Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal CancerAnuradha Krishnamurthy, Arvind Dasari, Anne M Noonan, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Cancers|April 27, 2024
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid TumorsS Lindsey Davis, Wells A Messersmith, W Thomas Purcell, et al.
Liver Cancer|May 14, 2026
A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular CarcinomaAnthony B El-Khoueiry, Christopher H Lieu, Ghassan K Abou-Alfa, et al.
Plos One|April 10, 2024
Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL)Hayley J Hawkins, Betelehem W Yacob, Monica E Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2017
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal CancerEfrat Dotan, Steven J Cohen, Alexander N Starodub, et al.
JAMA Network Open|May 24, 2024
Red Flag Signs and Symptoms for Patients With Early-Onset Colorectal Cancer: A Systematic Review and Meta-AnalysisJoshua Demb, Jennifer M Kolb, Jonathan Dounel, et al.
Frontiers in Oncology|April 16, 2026
Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer modelRobert W Lentz, Adrian T A Dominguez, Nicole Baranda Balmaceda, et al.
Molecular Cancer Therapeutics|January 30, 2016
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian CancerColin D Weekes, Laetitia E Lamberts, Mitesh J Borad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2020
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Scott Kopetz, Katherine A Guthrie, Van K Morris, et al.
Frontiers in Oncology|November 24, 2022
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse modelsJulie Lang, Alexis D Leal, Juan A Marín-Jiménez, et al.
Cancer Research|July 26, 2018
Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal CancerAnuradha Krishnamurthy, Arvind Dasari, Anne M Noonan, et al.
Pageof 7